Introduction Of Extended-Interval Dosing Of Ocrelizumab To Patients With Hypogammaglobulinaemia
By Mairi Cromarty, neurosciences clinical pharmacist, NHS Lothian
Project poster
More MS Academy Medication Projects
Identifying polypharmacy risk and improving medication optimisation in MS patients
By Dr Deepthi Vinayan Changaradil, consultant neurologist, Lewisham & Greenwich NHS Foundation Trust
Patient’s experience with subcutaneous Ocrelizumab at Lancashire Teaching Hospital NHS Foundation Trust
By Dr Suhaib Mohammed, neurology specialty registrar, Lancashire Teaching Hospitals NHS Foundation Trust
Intravenous vs Subcutaneous Natalizumab With Extended Interval Dosing: A Comparison
By Dr Pavlos Theodorou, neurology specialty registrar, University Hospitals Coventry and Warwickshire NHS Trust
Encouraging excellence, developing leaders, inspiring change
MS Academy was established in 2016 and in that time has accomplished a huge amount with exciting feedback demonstrating delegates feel inspired and energised along their personal and service development journeys. The various different levels of specialist MS training we offer are dedicated to case-based learning and practical application of cutting edge research.